# Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD

> **NCT02586155** · PHASE3 · COMPLETED · sponsor: **Resverlogix Corp** · enrollment: 2425 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Coronary Artery Disease

## Interventions

- **DRUG:** Apabetalone
- **DRUG:** Placebo
- **DRUG:** Atorvastatin
- **DRUG:** Rosuvastatin

## Key facts

- **NCT ID:** NCT02586155
- **Lead sponsor:** Resverlogix Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2020-11-30
- **Final completion:** 2021-06-21
- **Target enrollment:** 2425 (ACTUAL)
- **Last updated:** 2021-08-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02586155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02586155, "Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02586155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*